A Phase 3 interventional study of MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) and Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) in Influenza, Human, sponsored by Seqirus. Completed at 20 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-22.
Sponsored by Seqirus (part of CSL Limited) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing MF59 in Influenza, Human — 3 open to participants now, 3 under way, 1 of them phase 3. MF59 · Influenza, Human.
Among the 22 studies testing MF59 in Influenza, Human, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 6 in phase 3, and was the 17th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →3 of the 22 studies testing MF59 in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
National Taiwan University Hospital
Ages 50+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 10 · Phase 4 3
First in 2006; this study’s year is marked. 4 started in 2017.
This study's enrollment of 1,778 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 549 across the 22 interventional studies. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seqirus, one of the names counted as CSL Limited. Under that name alone:
Seqirus is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 10 (67%) have results posted.
51 studies in Influenza, Human by CSL Limited: none open now, none under way, none of them phase 3. Of 49 finished, 31 (63%) have results posted.
Among the 51 studies in Influenza, Human by CSL Limited, this one is the 15th largest by enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2017, is one of 19 in phase 3, and was the 36th registered.
CSL Limited’s Influenza, Human studies by the year they started, since 2005.
2 of the studies testing MF59 in Influenza, Human that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07485855Phase 3Asan Medical CenterInfluenza Vaccination Strategy for Patients With Hematologic Malignancy | 2027-04-30 |
| NCT07126652National Taiwan University HospitalSerological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing MF59 in Influenza, Human, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among CSL Limited’s 51 in Influenza, Human:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B strain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional eligibility criteria may be discussed by contacting the site.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
Biological: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
Biological: Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)
MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
Biological: MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
Immunogenicity Endpoint: The Geometric Mean Titer (GMT) and GMT Ratio for the Four Strains Included in the Vaccine, Non-inferiority Analysis.
The GMT of the post-vaccination (Day 22) hemagglutination inhibition (HI) titer. The GMT ratio was defined as the GMT for aTIV-1 (or aTIV-2) over the GMT for aQIV for all of the four strains.
Time frame: Day 22
Immunogenicity Endpoint: The Difference Between the Seroconversion Rate (SCR) for the Four Strains Included in the Vaccine, Non-inferiority Analysis
The SCR is defined as the percentage of subjects with either a pre-vaccination HI titer \< 1:10 and a post-vaccination HI titer \>= 1:40 or a pre-vaccination HI titer \>= 1:10 and a \>= 4-fold increase in post-vaccination HI titer. The SCR Difference is defined as the difference between the SCR of post- vaccination (Day 22) HI titer for aTIV-1 (or aTIV-2) and the SCR of post-vaccination (Day 22) HI titer for aQIV. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.
Time frame: Day 22
Immunogenicity Endpoint: The Percentage of Subjects Achieving SCR for Hemagglutination Inhibition (HI) Antibody for the Four Strains Included in the Vaccine.
The percentage of subjects vaccinated with aQIV achieving SCR at Day 22 was assessed for each of the 4 strains. SCR was defined as the percentage of subjects with either a pre-vaccination HI titer \<1:10 and a post-vaccination HI titer ≥1:40 or a pre-vaccination HI titer ≥1:10 and a ≥4-fold increase in post-vaccination HI titer. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving SCR for HI antibody should meet or exceed 30%.
Time frame: Day 22
Immunogenicity Endpoint: The Percent of Subjects Achieving an HI Antibody Titer ≥ 1:40 for the Four Strains Included in the Vaccines.
The percentage of subjects vaccinated with aQIV achieving HI antibody titers ≥ 1:40 at Day 22 was assessed for each of the 4 strains. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving a post-vaccination HI antibody titer ≥ 1:40 should meet or exceed 60%.
Time frame: Day 22
Immunogenicity Endpoint: Geometric Mean Titers (GMT) Against Homologous Strains
For the assessment of GMTs using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2. The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the GMT ratio (aTIV/aQIV) at Day 22.
Time frame: Day 1 and Day 22
Immunogenicity Endpoint: Geometric Mean Ratio (GMR) of Post Vaccination HI Titer Over the Pre-vaccination HI Titer Against Homologous Strains
The GMR was assessed as the postvaccination HI titer divided by the prevaccination HI titer (Day 22/Day 1). aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.
Time frame: Day 22/Day 1
Immunogenicity Endpoint: The Percentage of Subjects With a Titer ≥1:40 Against Homologous Strains
The percentage of subjects with HI titer of ≥1:40 at Day 1 (prevaccination) and Day 22 (postvaccination) was assessed for homologous strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.
Time frame: Day 1 and Day 22
Immunogenicity Endpoint: The Percentage of Subjects With SCR Against Homologous Strains
The SCR was defined as the percentage of subjects with either a prevaccination HI titer \<1:10 and a postvaccination HI titer ≥1:40 or a prevaccination HI titer ≥1:10 and a ≥4-fold increase in postvaccination HI titer. For assessment if SCR using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2. The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the difference in SCR (aTIV-aQIV) at Day 22.
Time frame: Day 22
Safety Endpoint: Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) Following Vaccination
Safety of vaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.
Time frame: Day 1 through Day 7
Safety Endpoint: Number of Subjects With Unsolicited AEs
Safety of vaccination was assessed in terms of percentage of subjects reporting unsolicited AEs up to 21 days after vaccination.
Time frame: Day 1 through Day 22
Safety Endpoint: Number of Subjects With Serious AEs (SAEs), AEs Leading to Withdrawal From the Study, New Onset of Chronic Diseases (NOCDs) and AEs of Special Interest (AESIs)
Safety of vaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, and AESIs and medically attended AE up to 180 days after vaccination.
Time frame: Day 1 through Day 181
20 study centers in the United States
| Milestone | aQIV | aTIV-1 | aTIV-2 |
|---|---|---|---|
| Started | 889 | 445 | 444 |
| Treated | 888 | 444 | 444 |
| Completed | 881 | 440 | 439 |
| Not completed | 8 | 5 | 5 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 5 | 4 | 4 |
| Withdrew: Death | 2 | 0 | 0 |
The GMT of the post-vaccination (Day 22) hemagglutination inhibition (HI) titer. The GMT ratio was defined as the GMT for aTIV-1 (or aTIV-2) over the GMT for aQIV for all of the four strains.
| Geometric mean titer | aQIV | aTIV-1 | aTIV-2 | aTIV-1/aTIV-2 |
|---|---|---|---|---|
| A/H1N1 | 65.01 (57.79 to 73.13) | NA (NA to NA) | NA (NA to NA) | 75.16 (66.68 to 84.72) |
| A/H3N2 | 294.91 (261.88 to 332.09) | NA (NA to NA) | NA (NA to NA) | 293.31 (259.91 to 330.99) |
| B/Yamagata | 24.67 (22.67 to 26.84) | 15.96 (14.48 to 17.59) | 24.30 (22.00 to 26.84) | NA (NA to NA) |
| B/Victoria | 30.78 (28.27 to 33.51) | 30.13 (27.31 to 33.24) | 21.80 (19.73 to 24.09) | NA (NA to NA) |
The SCR is defined as the percentage of subjects with either a pre-vaccination HI titer \< 1:10 and a post-vaccination HI titer \>= 1:40 or a pre-vaccination HI titer \>= 1:10 and a \>= 4-fold increase in post-vaccination HI titer. The SCR Difference is defined as the difference between the SCR of post- vaccination (Day 22) HI titer for aTIV-1 (or aTIV-2) and the SCR of post-vaccination (Day 22) HI titer for aQIV. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.
| percentage of subjects | aQIV | aTIV-1 | aTIV-2 |
|---|---|---|---|
| A/H1N1 | 35.21 (32 to 38.5) | 39.45 (34.8 to 44.2) | 37.41 (32.8 to 44.2) |
| A/H3N2 | 39.33 (36.1 to 42.7) | 39.70 (36.4 to 43.0) | 37.18 (32.6 to 41.9) |
| B/Yamagata | 16.4 (14.0 to 19.0) | NA (NA to NA) | 15.47 (12.2 to 19.2) |
| B/Victoria | 13.42 (11.2 to 15.9) | 12.16 (9.24 to 15.6) | NA (NA to NA) |
The percentage of subjects vaccinated with aQIV achieving SCR at Day 22 was assessed for each of the 4 strains. SCR was defined as the percentage of subjects with either a pre-vaccination HI titer \<1:10 and a post-vaccination HI titer ≥1:40 or a pre-vaccination HI titer ≥1:10 and a ≥4-fold increase in post-vaccination HI titer. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving SCR for HI antibody should meet or exceed 30%.
| Percentage of subjects | aQIV | aTIV-1 | aTIV-2 |
|---|---|---|---|
| A/H1N1 | 35.21 (32.03 to 38.48) | 39.45 (34.80 to 44.20) | 37.41 (32.8 to 40.20) |
| A/H3N2 | 39.33 (36.08 to 42.67) | 39.70 (36.43 to 43.04) | 37.18 (32.6 to 41.9) |
| B/Yamagata | 16.40 (14.0 to 19.03) | NA (NA to NA) | 15.47 (12.2 to 19.2) |
| B/Victoria | 13.42 (11.22 to 15.86) | 12.16 (9.24 to 15.60) | NA (NA to NA) |
The percentage of subjects vaccinated with aQIV achieving HI antibody titers ≥ 1:40 at Day 22 was assessed for each of the 4 strains. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving a post-vaccination HI antibody titer ≥ 1:40 should meet or exceed 60%.
| Percentage of subjects | aQIV | aTIV-1 | aTIV-2 |
|---|---|---|---|
| A/H1N1 | 69.38 (66.20 to 72.43) | 71.79 (67.31 to 75.97) | 68.82 (64.23 to 73.16) |
| A/H3N2 | 93.92 (92.12 to 95.41) | 94.72 (92.19 to 96.63) | 94.92 (92.41 to 96.79) |
| B/Yamagata | 32.80 (29.69 to 36.03) | 21.79 (18.00 to 25.96) | 36.95 (32.39 to 41.69) |
| B/Victoria | 38.19 (34.95 to 41.51) | 36.93 (32.38 to 41.65) | 24.48 (20.50 to 28.81) |
For the assessment of GMTs using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2. The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the GMT ratio (aTIV/aQIV) at Day 22.
| geometric mean titer | aQIV | aTIV-1 | aTIV-2 | aTIV-1/aTIV-2 |
|---|---|---|---|---|
| A/H1N1 Day 1 | 19.07 (17.66 to 20.60) | NA (NA to NA) | NA (NA to NA) | 18.77 (17.47 to 20.17) |
| A/H1N1 Day 22 | 57.07 (52.67 to 61.84) | NA (NA to NA) | NA (NA to NA) | 63.73 (58.60 to 69.32) |
| A/H3N2 Day 1 | 73.27 (66.36 to 80.90) | NA (NA to NA) | NA (NA to NA) | 71.83 (65.39 to 78.90) |
| A/H3N2 Day 22 | 245.85 (225.57 to 267.95) | NA (NA to NA) | NA (NA to NA) | 236.27 (217.53 to 256.63) |
| B/Yamagata Day 1 | 10.41 (9.86 to 10.98) | NA (NA to NA) | 10.76 (9.97 to 11.61) | NA (NA to NA) |
| B/Yamagata Day 22 | 21.15 (19.75 to 22.66) | NA (NA to NA) | 20.74 (18.86 to 22.80) | NA (NA to NA) |
| B/Victoria Day 1 | 14.15 (13.30 to 15.05) | 15.18 (13.85 to 16.64) | NA (NA to NA) | NA (NA to NA) |
| B/Victoria Day 22 | 24.91 (23.21 to 26.74) | 25.54 (23.03 to 28.33) | NA (NA to NA) | NA (NA to NA) |
The GMR was assessed as the postvaccination HI titer divided by the prevaccination HI titer (Day 22/Day 1). aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.
| geometric mean ratio | aQIV | aTIV-1 | aTIV-2 | aTIV-1/aTIV-2 |
|---|---|---|---|---|
| A/H1N1 | 2.99 (2.78 to 3.22) | NA (NA to NA) | NA (NA to NA) | 3.40 (3.14 to 3.67) |
| A/H3N2 | 3.36 (3.07 to 3.66) | NA (NA to NA) | NA (NA to NA) | 3.29 (3.02 to 3.59) |
| B/Yamagata | 2.03 (1.92 to 2.15) | NA (NA to NA) | 1.93 (1.79 to 2.08) | NA (NA to NA) |
| B/Victoria | 1.76 (1.66 to 1.86) | 1.68 (1.55 to 1.82) | NA (NA to NA) | NA (NA to NA) |
The percentage of subjects with HI titer of ≥1:40 at Day 1 (prevaccination) and Day 22 (postvaccination) was assessed for homologous strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.
| percentage of subjects | aQIV | aTIV-1 | aTIV-2 | aTIV-1/aTIV-2 |
|---|---|---|---|---|
| A/H1N1 Day 1 | 33.26 (30.13 to 36.49) | NA (NA to NA) | NA (NA to NA) | 31.07 (28.00 to 34.27) |
| A/H1N1 Day 22 | 69.38 (66.20 to 72.43) | NA (NA to NA) | NA (NA to NA) | 70.31 (67.15 to 73.33) |
| A/H3N2 Day 1 | 70.64 (67.50 to 73.65) | NA (NA to NA) | NA (NA to NA) | 70.66 (67.50 to 73.67) |
| A/H3N2 Day 22 | 93.92 (92.12 to 95.41) | NA (NA to NA) | NA (NA to NA) | 94.82 (93.13 to 96.20) |
| B/Yamagata Day 1 | 11.12 (9.11 to 13.40) | NA (NA to NA) | 11.55 (8.69 to 14.94) | NA (NA to NA) |
| B/Yamagata Day 22 | 32.80 (26.69 to 36.03) | NA (NA to NA) | 36.95 (32.39 to 41.69) | NA (NA to NA) |
| B/Victoria Day 1 | 19.72 (17.13 to 22.52) | 22.71 (18.86 to 26.93) | NA (NA to NA) | NA (NA to NA) |
| B/Victoria Day 22 | 38.19 (34.95 to 41.51) | 36.93 (32.38 to 41.65) | NA (NA to NA) | NA (NA to NA) |
The SCR was defined as the percentage of subjects with either a prevaccination HI titer \<1:10 and a postvaccination HI titer ≥1:40 or a prevaccination HI titer ≥1:10 and a ≥4-fold increase in postvaccination HI titer. For assessment if SCR using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2. The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the difference in SCR (aTIV-aQIV) at Day 22.
| Percentage of subjects | aQIV | aTIV-1 | aTIV-2 | aTIV-1/aTIV-2 |
|---|---|---|---|---|
| A/H1N1 | 35.21 (32.03 to 38.48) | NA (NA to NA) | NA (NA to NA) | 38.43 (35.19 to 41.76) |
| A/H3N2 | 39.33 (36.08 to 42.67) | NA (NA to NA) | NA (NA to NA) | 39.70 (36.43 to 43.04) |
| B/Yamagata | 16.40 (14.00 to 19.03) | NA (NA to NA) | 15.47 (12.20 to 19.23) | NA (NA to NA) |
| B/Victoria | 13.42 (11.22 to 15.86) | 12.16 (9.24 to 15.60) | NA (NA to NA) | NA (NA to NA) |
Safety of vaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.
| Participants | aQIV | aTIV-1 | aTIV-2 |
|---|---|---|---|
| Any local solicited AE | 385 | 170 | 167 |
| Any systemic solicited AE | 231 | 107 | 110 |
Safety of vaccination was assessed in terms of percentage of subjects reporting unsolicited AEs up to 21 days after vaccination.
| Participants | aQIV | aTIV-1 | aTIV-2 |
|---|---|---|---|
| Safety Endpoint: Number of Subjects With Unsolicited AEs | 136 | 50 | 68 |
Safety of vaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, and AESIs and medically attended AE up to 180 days after vaccination.
| Participants | aQIV | aTIV-1 | aTIV-2 |
|---|---|---|---|
| SAEs | 37 | 28 | 18 |
| AEs leading to withdrawal | 0 | 0 | 0 |
| NOCDs | 23 | 16 | 14 |
| AESIs | 1 | 1 | 0 |
Collected over SAEs and unsolicited AEs: Day 1 through 181; Solicited AEs: Day 1 through 7. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| aQIV | 2/888 (0.2%) | 37/888 (4.2%) | 461/888 (51.9%) |
| aTIV-1 | 0/444 (0%) | 28/444 (6.3%) | 217/444 (48.9%) |
| aTIV-2 | 0/444 (0%) | 18/444 (4.1%) | 215/444 (48.4%) |
| Event | aQIV | aTIV-1 | aTIV-2 |
|---|---|---|---|
| PneumoniaInfections and infestations | 7/888 | 4/444 | 1/444 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 3/888 | 3/444 | 0/444 |
| Coronary artery diseaseCardiac disorders | 1/888 | 1/444 | 2/444 |
| InfluenzaInfections and infestations | 1/888 | 0/444 | 2/444 |
| Carotid artery stenosisNervous system disorders | 1/888 | 2/444 | 0/444 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/888 | 1/444 | 0/444 |
| Atrial fibrillationCardiac disorders | 1/888 | 0/444 | 1/444 |
| Angina pectorisCardiac disorders | 0/888 | 0/444 | 1/444 |
| Myocardial infarctionCardiac disorders | 0/888 | 1/444 | 0/444 |
| Sinus node dysfunctionCardiac disorders | 0/888 | 1/444 | 0/444 |
| Event | aQIV | aTIV-1 | aTIV-2 |
|---|---|---|---|
| PainGeneral disorders | 275/888 | 125/444 | 109/444 |
| RednessGeneral disorders | 188/888 | 77/444 | 81/444 |
| FatigueGeneral disorders | 144/888 | 67/444 | 52/444 |
| SwellingGeneral disorders | 134/888 | 69/444 | 64/444 |
| HeadacheNervous system disorders | 105/888 | 46/444 | 49/444 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 80/888 | 37/444 | 31/444 |
| MyalgiaMusculoskeletal and connective tissue disorders | 71/888 | 34/444 | 31/444 |
| EcchymosisGeneral disorders | 69/888 | 28/444 | 23/444 |
| DiarrheaGastrointestinal disorders | 48/888 | 24/444 | 30/444 |
| OtherGeneral disorders | 48/888 | 12/444 | 17/444 |
| Age, Continuous(years) | aQIV | aTIV-1 | aTIV-2 | Total |
|---|---|---|---|---|
| Mean | 72.4 ± 5.54 | 72.4 ± 5.60 | 72.6 ± 5.46 | 72.5 ± 5.53 |
| Sex: Female, Male(Participants) | aQIV | aTIV-1 | aTIV-2 | Total |
|---|---|---|---|---|
| Female | 517 | 249 | 241 | 1007 |
| Male | 372 | 196 | 203 | 771 |
| Race/Ethnicity, Customized(Participants) | aQIV | aTIV-1 | aTIV-2 | Total |
|---|---|---|---|---|
| White | 814 | 403 | 411 | 1628 |
| Black or African American | 59 | 37 | 29 | 125 |
| Asian | 9 | 2 | 1 | 12 |
| Native Hawaiian or Pacific Islander | 1 | 1 | 0 | 2 |
| American Indian or Alaska Native | 5 | 0 | 2 | 7 |
| Other | 1 | 2 | 1 | 4 |
| Race/Ethnicity, Customized(Participants) | aQIV | aTIV-1 | aTIV-2 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 59 | 37 | 31 | 127 |
| Not Hispanic or Latino | 827 | 408 | 410 | 1645 |
| Not Reported | 2 | 0 | 2 | 4 |
| Unknown | 1 | 0 | 1 | 2 |
| Region of Enrollment(participants) | aQIV | aTIV-1 | aTIV-2 | Total |
|---|---|---|---|---|
| United States | 889 | 445 | 444 | 1778 |
| Height(cm) | aQIV | aTIV-1 | aTIV-2 | Total |
|---|---|---|---|---|
| Mean | 167.54 ± 9.350 | 167.92 ± 10.535 | 168.38 ± 10.646 | 167.84 ± 9.990 |
| Weight(kg) | aQIV | aTIV-1 | aTIV-2 | Total |
|---|---|---|---|---|
| Mean | 83.24 ± 19.064 | 84.18 ± 8.963 | 84.24 ± 17.825 | 83.73 ± 18.731 |
| BMI(kg/m^2) | aQIV | aTIV-1 | aTIV-2 | Total |
|---|---|---|---|---|
| Mean | 29.60 ± 6.157 | 29.79 ± 5.858 | 29.69 ± 5.647 | 29.67 ± 5.956 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2017 to primary completion in Dec 2017, 1 month.
Results were first posted in Jul 2020, 2 years 7 months after primary completion. A results delay was requested in Nov 2018.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 1 month is below that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MF59